This is a phase 2, open-label, multicenter study evaluating axicabtagene ciloleucel (axi-cel)
as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are
ineligible to receive Autologous Stem Cell Transplantation but eligible to receive CAR T-cell
Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy
directed against CD19 which has been approved for the treatment of relapse/refractory diffuse
large B-cell lymphoma DLBCL and primary mediastinal large B-cell lymphoma (PMBCL) after 2 or
more lines of systemic therapy.
But administrating CAR T-cells earlier in the therapeutic strategy may be beneficial to
Axi-cel will improve the outcome of patients with DLBCL who are refractory or relapse early
(i.e. within 1 year from end of treatment) after first-line therapy and who are not eligible
for Autologous Stem Cell Transplantation (ASCT).
Transplant-ineligible patients will include those who are deemed ineligible for high-dose
chemotherapy and Hematopoietic Stem Cell Transplantation (HSCT) due to age, comorbidity, or
The primary endpoint will be complete metabolic response (CMR) at 3 months after Axi-cel
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.